Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
Public ClinicalTrials.gov record NCT04447118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Study identification
- NCT ID
- NCT04447118
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Industry
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Interventions
- Pyrotinib Drug
- Docetaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 10, 2020
- Primary completion
- Jun 1, 2023
- Completion
- Dec 5, 2024
- Last update posted
- Dec 18, 2025
2020 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California - Irvine Medical Center | Orange | California | 92868 | — |
| University of California (UC) Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Innovative Clinical Research Institute | Whittier | California | 33756 | — |
| Florida Cancer Specialists South Divisio | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists North Divisio | St. Petersburg | Florida | 33701 | — |
| University of Kansas Medical Center (KUMC) | Kansas City | Kansas | 66160 | — |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Tennessee Oncology | Nashville | Tennessee | 33756 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Summit Cancer Centers - North Spokane | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04447118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04447118 live on ClinicalTrials.gov.